Clinical trials: Lipoprotein-apheresis
Lipoprotein(a), Lipoprotein-apheresis
Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patients With Chronic Kidney Disease ; ( LiPo-A )
Lipoprotein-apheresis DFPP has been performed in patients with Lp(a) levels greater than 125 nmol/L. In this report, data will be presented on five hemodialysis patients with significantly elevated Lp(a) levels (>200 nmol/L) who…
- Conditions
- Lipoprotein(a), Lipoprotein-apheresis, Double-filtration Plasmapheresis, Hemodialysis Complication
- Trial name
- LiPo-A (NCT07390604)
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Homozygous Familial Hypercholesterolemia
Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia
Homozygous familial hypercholesterolemia (HoFH) is characterized by a six- to eight-fold raise in plasma LDL-cholesterol (LDL-C) concentrations and atherosclerotic coronary artery disease usually occur before the age of 20 if…
- Trial name
- APHERESE (NCT02286596)
- Testing
- heparin-induced extracorporeal LDL precipitation, dextran sulfate adsorption
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- Laval University
Hypercholesterolemia
(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol
The primary objective of the study is to demonstrate that the performance of the modified Plasmat® Futura H.E.L.P. Apheresis System is non-inferior to the current FDA approved Plasmat® Secura H.E.L.P Apheresis System for use…
- Trial name
- FUTURA (NCT00526058)
- Testing
- Secura then Futura, Futura then Secura
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- B. Braun Medical Inc.
Hyperlipoproteinemia (a)
An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This non-randomized, open-label extension study provides post-trial access to pelacarsen (TQJ230) to participants in Germany with hyperlipoproteinemia(a) and established cardiovascular disease who have successfully completed the…
- Trial name
- OLE (NCT05900141)
- Testing
- Pelacarsen
- Where
- 9 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Heterozygous Familial Hypercholesterolemia
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
The primary objective of the study is to evaluate the effect of alirocumab 150 mg every 2 weeks (Q2W) in comparison with placebo on the frequency of low-density lipoprotein (LDL) apheresis treatments in participants with…
- Trial name
- ODYSSEY ESCAPE (NCT02326220)
- Testing
- Alirocumab
- Where
- 13 sites in United States, Germany
- Volunteers
- 62 people
- Sponsor
- Regeneron Pharmaceuticals
Hypercholesterolemia
Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment
To evaluate the efficacy of subcutaneous (SC) evolocumab, compared to regularly scheduled low-density lipoprotein cholesterol (LDL-C) apheresis, on reducing the need for future apheresis.
- Trial name
- NCT02585895
- Testing
- Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
- Where
- 17 sites in United States, Australia and 6 more
- Volunteers
- 39 people
- Sponsor
- Amgen
Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia
Effect of Lipoprotein(a) Elimination by Lipoprotein Apheresis on Cardiovascular Outcomes
This multicenter multinational prospective two-arm matched-pair observational study aims to establish a prospective comparison of active lipoprotein apheresis treatment approved and conducted according to German guidelines for…
- Trial name
- MultiSELECt (NCT02791802)
- Where
- 12 sites in Germany
- Volunteers
- 1,000 people
- Sponsor
- Technische Universität Dresden
Familial Hypercholesterolemia
Low-Density Lipoprotein (LDL) Apheresis Using H.E.L.P. Therapy
The objectives of this post-surveillance study are to continue to evaluate the safety and effectiveness of the H.E.L.P. System. The safety and effectiveness will be assessed by evaluating the occurrence of death, cardiovascular…
- Trial name
- Secura (NCT00916643)
- Testing
- HELP Secura (apheresis treatment)
- Volunteers
- 113 people
- Sponsor
- B. Braun Medical Inc.
Lipoproteinemia, Apheresis Related Complication
Long-term Characterization of Lipoprotein Apheresis Technologies for Individual Device Adaption (LOLIDA)
Lipoprotein apheresis is often applied as the final treatment of patient with severe and medication resistant dyslipidemia and progressive atherosclerosis.
- Conditions
- Lipoproteinemia, Apheresis Related Complication, Cardiovascular Diseases
- Trial name
- LOLIDA (NCT05181969)
- Testing
- Dextran sulfate absorption (LIPOSORBER® D - Kaneka Pharma Europe NV), Lipid filtration (Octo Nova®, Diamed Medizintechnik), Direct absorption of lipoproteins (DALI®; ADS 4008, Fresenius)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Technische Universität Dresden
Atherosclerosis, Coronary Disease
Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis
To evaluate whether specific lipoprotein(a) apheresis on the top of optimal medical therapy could affect atherosclerotic disease burden in coronary and carotid arteries of coronary heart disease patients with elevated Lp(a)…
- Conditions
- Atherosclerosis, Coronary Disease, Carotid Artery Diseases
- Trial name
- LaRCA (NCT02133807)
- Testing
- Specific Lp(a) apheresis
- Where
- Russia
- Volunteers
- 32 people
- Sponsor
- Russian Cardiology Research and Production Center
Familial Hypercholesterolemia
Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is an autosomal codominant single-gene disorder caused by mutations in the LDL receptor gene that disrupt the normal clearance of LDL particles from the plasma compartment.
- Trial name
- LA-PBMC (NCT02462655)
- Testing
- Pre-lipid apheresis, Post-lipid apheresis
- Where
- Canada
- Volunteers
- 9 people
- Sponsor
- Laval University
Hyperlipoproteinemia(a)
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany
Phase III study to test the hypothesis that treatment with pelacarsen (TQJ230) 80 mg Q4W compared to placebo significantly reduces the rate of lipoprotein apheresis in patients with hyperlipoproteinemia (a) and established…
- Trial name
- NCT05305664
- Testing
- Pelacarsen (TQJ230) 80 mg s.c.
- Where
- 13 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Refractory Angina, Raised Lipoprotein(a)>50mg/dL or >500mg/L
Lipoprotein Apheresis in Refractory Angina Study
The goal of this study is to determine the impact of apheresis on clinical parameters and symptoms of patients with refractory angina and raised Lp(a).
- Trial name
- NCT01796912
- Testing
- Lipoprotein Apheresis
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Imperial College London
Hypercholesterolemia, Familial, Dyslipidemias
Comparison of the Plasma Lipoprotein Apheresis Systems DIAMED and MONET vs. the Whole Blood Apheresis System DALI
The clinical Investigation will be performed to compare the safety and effectiveness of the CE certified and established lipoprotein apheresis systems MONET vs. DALI and DIAMED vs.
- Conditions
- Hypercholesterolemia, Familial, Dyslipidemias, Cardiovascular Diseases
- Trial name
- DIAMOND-2018 (NCT03795038)
- Testing
- Lipoprotein Apheresis MONET and DALI, Lipoprotein Apheresis DIAMED and DALI
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Familial Hypercholesterolemia
Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers
The primary objective of this study is to measure how LDL apheresis affects levels of inflammatory and cholesterol markers in human beings.
- Trial name
- INFLAME (NCT01138371)
- Testing
- LDL Apheresis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Emory University
Hyperlipoproteinemia(a), Progressive Cardiovascular Disease
Randomized Controlled Trial of Lipid Apheresis in Patients With Elevated Lipoprotein(a)
Lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease. Non-medical treatment measures (e.g. dietary therapy or weight loss) can hardly influence Lp(a) plasma concentrations.
- Trial name
- ELAILa (NCT01064934)
- Testing
- Lipid apheresis, Standard care
- Where
- Germany
- Sponsor
- Charite University, Berlin, Germany